ECLIPSE
Curium's PSMA radioligand met its progression endpoint; survival data and an FDA filing are pending.
~400 men; rPFS primary endpoint met (2025); OS maturing; study completion projected 2029; FDA submission plan under discussion.
Setting
PSMA-positive mCRPC after ARPI, taxane-naive: 177Lu-PSMA-I&T (7.4 GBq × 6) vs ARPI switch
Phase
Phase 3
Sponsor
Curium
Registry
Headline result
rPFS significantly improved.
Reported
2025
Enrolled
439
Replication
Consistent with PSMAfore for the pre-chemotherapy setting; OS pending.
In plain words
What these results mean for people, not percentages
Radiographic progression-free survivalprimarysurrogate endpoint
- Numbers are not recorded here for this endpoint. 177Lu-PSMA-I&T: Met per sponsor; medians pending publication; ARPI switch.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: PSMA-positive mCRPC after ARPI, taxane-naive: 177Lu-PSMA-I&T (7.4 GBq × 6) vs ARPI switch. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (PSMA); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
439 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Radiographic progression-free survivalprimary | 177Lu-PSMA-I&T | — | Met per sponsor; medians pending publication | — | — | link |
| ARPI switch | — | — |
Replication
Consistent with PSMAfore for the pre-chemotherapy setting; OS pending.Pages like this
not linked directly; found by shared links- TrialSPLASH
Shares 177Lu-PSMA-I&T, Prostate cancer.
- PersonPeter Bartenstein
Shares 177Lu-PSMA-I&T, Prostate cancer.
- CompanyLantheus
Shares 177Lu-PSMA-I&T, Prostate cancer.
- CompanyCurium
Shares 177Lu-PSMA-I&T, Prostate cancer.